基于数字乳腺断层摄影乳腺摄影估算的肿瘤体积倍增时间可区分浸润性乳腺癌与良性病变
本研究回顾性分析了2017至2020年间数字乳腺断层摄影筛查中当前及回顾性可见的可疑病灶,经活检证实为浸润性乳腺癌或良性病变。28例浸润性导管癌或浸润性小叶癌与40例良性病变患者中,浸润性乳腺癌的平均肿瘤体积倍增时间显著短于良性病变(0.84年 vs 2.5年,p=0.0025),肿瘤体积倍增时间小于1年者浸润性癌的比值比为6.33(95%CI 2.18-18.43)。
要点
- 浸润性乳腺癌的平均肿瘤体积倍增时间显著短于良性病变(0.84年 vs 2.5年,p=0.0025)。
- 肿瘤体积倍增时间小于1年者浸润性癌的比值比为6.33(95%CI 2.18-18.43)。
- 校正年龄、病灶最大径和体积后,较短的肿瘤体积倍增时间是唯一与浸润性癌结局显著相关的尺寸变量。
核心结论
- 在当前及回顾性可见的筛查乳腺摄影中,浸润性乳腺癌与较短的肿瘤体积倍增时间相关,而良性病变的肿瘤体积倍增时间较长;若在更大规模研究中证实其足以预测良性,与既往检查相比肿瘤体积倍增时间较长的可见病灶可能避免额外影像检查和/或活检。
研究设计与样本
- 回顾性研究,纳入2017至2020年间数字乳腺断层摄影筛查中当前及回顾性可见、经活检证实的可疑病灶,共28例浸润性导管癌或浸润性小叶癌患者和40例良性病变患者;由四名经验丰富的放射科医生记录检查日期、乳腺密度、病灶类型、病灶直径和形态,采用逻辑回归模型评估浸润性癌结局与病灶尺寸指标(最大径、平均径、体积、肿瘤体积倍增时间)的关联。
诊断标准与关键数值
- 浸润性乳腺癌平均肿瘤体积倍增时间为0.84年,良性病变为2.5年,两组差异有统计学意义(p=0.0025);肿瘤体积倍增时间小于1年者浸润性癌的比值比为6.33(95%CI 2.18-18.43);校正年龄、病灶最大径和病灶体积的逻辑回归显示,较短的肿瘤体积倍增时间是唯一与浸润性癌结局显著相关的尺寸变量。
临床应用与阅片要点
- 作者认为,若在更大规模研究中证实肿瘤体积倍增时间足以预测良性,与既往检查相比肿瘤体积倍增时间较长的可见病灶可能避免额外影像检查和/或活检。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to determine whether lesion size metrics on consecutive screening mammograms could predict malignant invasive carcinoma versus benign lesion outcome.
METHODS: We retrospectively reviewed suspicious screen-detected lesions confirmed by biopsy to be invasive breast cancers or benign that were visible on current and in-retrospect prior screening mammograms performed with digital breast tomosynthesis from 2017 to 2020. Four experienced radiologists recorded mammogram dates, breast density, lesion type, lesion diameter, and morphology on current and prior exams. We used logistic regression models to evaluate the association of invasive breast cancer outcome with lesion size metrics such as maximum dimension, average dimension, volume, and tumor volume doubling time (TVDT).
RESULTS: Twenty-eight patients with invasive ductal carcinoma or invasive lobular carcinoma and 40 patients with benign lesions were identified. The mean TVDT was significantly shorter for invasive breast cancers compared to benign lesions (0.84 vs. 2.5 years; p = 0.0025). Patients with a TVDT of less than 1 year were shown to have an odds ratio of invasive cancer of 6.33 (95% confidence interval, 2.18-18.43). Logistic regression adjusted for age, lesion maximum dimension, and lesion volume demonstrated that shorter TVDT was the size variable significantly associated with invasive cancer outcome.
CONCLUSION: Invasive breast cancers detected on current and in-retrospect prior screening mammograms are associated with shorter TVDT compared to benign lesions. If confirmed to be sufficiently predictive of benignity in larger studies, lesions visible on mammograms which in comparison to prior exams have longer TVDTs could potentially avoid additional imaging and/or biopsy.
KEY POINTS: • We propose tumor volume doubling time as a measure to distinguish benign from invasive breast cancer lesions. • Logistic regression results summarized the utility of the odds ratio in retrospective clinical mammography data.
引用
- Sadeghipour, Tseng, Anderson, et al. Tumor volume doubling time estimated from digital breast tomosynthesis mammograms distinguishes invasive breast cancers from benign lesions. Eur Radiol. 2022. PMID: 35779088. doi:10.1007/s00330-022-08966-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。